Search results for "Progression"

showing 10 items of 1251 documents

Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians.

2017

<b><i>Purpose:</i></b> To assess the natural disease progression of high myopia in Caucasians considered at risk for the development of myopic choroidal neovascularization (mCNV). <b><i>Methods:</i></b> Subjects were recruited in 25 clinical sites between June 2014 and June 2016. Main inclusion criteria included axial length of ≥26 mm, best-corrected visual acuity ≥0.05 decimal equivalent and presence of at least one out of five predefined morphological disease risk criteria. These were (1) subfoveal choroidal thinning < 50 µm, (2) enhanced choroidal curvature length > 6,300 µm, (3) lacquer cracks, (4) patchy atrophy &#x3…

AdultMalemedicine.medical_specialtyVisual acuityVisual AcuityDiseaseWhite People03 medical and health sciencesYoung Adult0302 clinical medicineAtrophyMyopic choroidal neovascularizationOphthalmologySurveys and QuestionnairesmedicineHumansProspective StudiesFluorescein AngiographyAgedAged 80 and overbusiness.industryChoroidPathological myopiaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsChoroidal NeovascularizationClinical trialNatural historyOphthalmologyAxial Length EyeResearch DesignBaseline characteristicsMyopia Degenerative030221 ophthalmology & optometryDisease ProgressionFemalesense organsmedicine.symptomAtrophybusiness030217 neurology & neurosurgeryTomography Optical CoherenceFollow-Up StudiesOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of >500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

2005

: Background: Splenic marginal zone lymphoma (SMZL) is an infrequent B-cell neoplasm that pursues an indolent course. Signs and symptoms, mostly related to hypersplenism, are successfully managed by splenectomy. However, the therapy of patients who are not fit for a surgical procedure or who relapse after splenectomy, is still an unsettled issue. Patients and methods: We report a phase-II study on 16 patients with SMZL, three therapy naive and 13 pretreated, all showing systemic symptoms or progressive worsening of peripheral cytopenia, who were treated with pentostatin at a dose of 4 mg/m2 every other week for 6–10 wk. In relapsed patients, the median interval between diagnosis and treatme…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSplenectomyPurine analogueDrug Administration SchedulemedicinePentostatinHumansProgression-free survivalSplenic marginal zone lymphomaLymphocytesAgedCytopeniaDeoxycoformycinbusiness.industrySplenic NeoplasmsRemission InductionNeoplasms Second PrimaryHematologyGeneral MedicineLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseSMZLSurvival AnalysisSurgerysplenic marginal zonelymphomaDeoxycoformycinFemaleSplenic LymphomabusinessPentostatinvillous lymphocytesmedicine.drugEuropean journal of haematology
researchProduct

Progression of Coronary Artery Calcification in Predialysis Patients

2006

<i>Background:</i> In patients on dialysis coronary artery calcification (CAC) rapidly proceeds due to impaired mineral metabolism and/or exogenous calcium load. Progression has not been assessed in patients with chronic kidney disease not yet requiring dialysis (CKD patients). In this study, rate and determinants of CAC progression have been evaluated in CKD patients who are exposed to minor derangement of mineral metabolism and calcium load. <i>Methods:</i> Consecutive patients were enrolled. Exclusion criteria were: symptomatic coronary disease, arrhythmia, myocardial infarction, and diabetes. Serum calcium, phosphorus, parathyroid hormone, homocysteine, C-reactiv…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentchemistry.chemical_elementCoronary Artery DiseaseCalciumCoronary artery diseaseRenal DialysisCoronary artery calcification Predialysis patients Phosphorus Progression of calcificationCalcinosisInternal medicinemedicineHumansMineral metabolismIn patientDialysisbusiness.industryDisease progressionCalcinosisnutritional and metabolic diseasesMiddle Agedmedicine.diseaseRadiographychemistryNephrologyCoronary artery calcificationChronic DiseaseDisease ProgressionCardiologyFemaleKidney DiseasesbusinessAmerican Journal of Nephrology
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort

2018

Importance Given that hypertension remains a leading risk factor for chronic disease globally, there are substantial ongoing efforts to define the optimal range of blood pressure (BP). Objective To identify a common threshold level above which BP rise tends to accelerate in progression toward hypertension. Design, Setting, and Participants This longitudinal, community-based epidemiological cohort study of adults enrolled in Framingham, Massachusetts, included 1252 participants (mean [SD] age, 35.3 [2.7] years) from the Framingham Original Cohort, of whom 790 (63.1%) were women. Each participant contributed up to 28 serial examinations of standardized resting BP measurements between 1948 and…

AdultMalemedicine.medical_specialtysystolic blood pressuresegmented mixed modelHemodynamicsBlood Pressurethreshold value030204 cardiovascular system & hematology03 medical and health sciencesSex Factors0302 clinical medicineFramingham Heart StudyInternal medicineHumansMedicineLongitudinal Studies030212 general & internal medicineAge of OnsetRisk factorAgedAged 80 and overFramingham Risk Scorebusiness.industryBrief ReportAge FactorsMiddle Agedta3121Blood pressureMassachusettsHypertensionCohortDisease ProgressionCardiologyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology

2019

Background: Erythropoietin (EPO) is a cytokine primarily involved in the regulation of erythropoiesis. In response to hypoxia–ischemia, hypoxia-inducible factor 1 induces EPO production, which, in turn, inhibits apoptosis of erythroid progenitor cells. By the same mechanism and acting through other signaling pathways, EPO exerts neuroprotective effects. Increased resistance to hypoxia and decreased apoptosis are thought to be important mechanisms for tumor progression, including malignant glioma. Because recent studies have demonstrated that EPO and its receptor (EPOR) are expressed in several tumors and can promote tumor growth, in the present study, we investigated EPO and EPOR expression…

AdultMalemedicine.medical_treatmentBlotting WesternErythropoietin receptor03 medical and health sciences0302 clinical medicineGliomaCell Line TumormedicineReceptors ErythropoietinAnimalsHumansErythropoietinAgedPlatelet Endothelial Cell Adhesion Moleculebusiness.industryBrain NeoplasmsGliomaMiddle Agedmedicine.diseaseImmunohistochemistryRats Inbred F344Recombinant ProteinsErythropoietin receptorTumor BurdenPlatelet Endothelial Cell Adhesion Molecule-1Disease Models AnimalCytokineKi-67 AntigenApoptosisErythropoietinTumor progressionErythropoietin; Erythropoietin receptor; Glioma030220 oncology & carcinogenesisCancer researchErythropoiesisSurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryNeoplasm Transplantationmedicine.drugErythropoietin Erythropoietin receptor Glioma
researchProduct

Wheat consumption leads to immune activation and symptom worsening in patients with familial mediterranean fever : a pilot randomized trial

2020

We have identified a clinical association between self-reported non-celiac wheat sensitivity (NCWS) and Familial Mediterranean Fever (FMF). Objectives: A) To determine whether a 2-week double-blind placebo-controlled (DBPC) cross-over wheat vs. rice challenge exacerbates the clinical manifestations of FMF

AdultMalenon-celiac wheat sensitivityCD14 lymphocytesLipopolysaccharide Receptors610 Medizinlcsh:TX341-641Wheat HypersensitivityMonocytesArticleDouble-Blind MethodAIDAI score610 Medical sciencesHumansTriticumCross-Over Studiesinterleukin-1betaTumor Necrosis Factor-alphaCD14 lymphocytefood and beveragesFamilial Mediterranean FeverDisease ProgressionFemaletumor necrosis factor-αlcsh:Nutrition. Foods and food supplyamylase trypsin inhibitor
researchProduct

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95…

AdultOncologyEribulin Mesylatemedicine.medical_specialtyeribulin mesylatemedicine.medical_treatmentTriple Negative Breast Neoplasmschemotherapytriple negative metastatic breast cancer03 medical and health scienceschemistry.chemical_compound0302 clinical medicineadjuvantInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapy; Efficacy outcomes; Eribulin mesylate; Toxicity outcomes; Triple negative metastatic breast cancerProgression-free survivalFuransAdverse effectTriple-negative breast cancerAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapybusiness.industryRetrospective cohort studyGeneral MedicineKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerNeoadjuvant TherapyProgression-Free SurvivalchemistryChemotherapy AdjuvantFemale030211 gastroenterology & hepatologytoxicity outcomesefficacy outcomeschemotherapy; efficacy outcomes; eribulin mesylate; toxicity outcomes; triple negative metastatic breast cancer; adult; aged; aged; 80 and over; antineoplastic combined chemotherapy protocols; chemotherapy; adjuvant; female; furans; humans; ketones; middle aged; neoadjuvant therapy; neoplasm staging; progression-free survival; retrospective studies; triple negative breast neoplasmsbusinessResearch PaperEribulinInternational Journal of Medical Sciences
researchProduct